Moderna: positive study data in RSV

(CercleFinance.com) - On Tuesday evening Moderna announced positive initial data from its pivotal Phase 3 efficacy trial ConquerRSV evaluating mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in the elderly.


mRNA-1345 demonstrated 83.7% vaccine efficacy against RSV lower respiratory tract disease, defined as two or more symptoms in the elderly. It was generally well tolerated and no safety issues were identified.

The trial is ongoing and further efficacy analyses are planned as cases accumulate, including for severe RSV. Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval.


Copyright (c) 2023 CercleFinance.com. All rights reserved.